➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,709,517

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,709,517
Title:Diarylhydantoin compounds
Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
Inventor(s): Sawyers; Charles L. (New York, NY), Jung; Michael E. (Los Angeles, CA), Chen; Charlie D. (Los Angeles, CA), Ouk; Samedy (Costa Mesa, CA), Welsbie; Derek (Northridge, CA), Tran; Chris (New York, NY), Wongvipat; John (Nanuet, NY), Yoo; Dongwon (Los Angeles, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:11/433,829
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,709,517
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,709,517

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astellas XTANDI enzalutamide CAPSULE;ORAL 203415-001 Aug 31, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Astellas XTANDI enzalutamide TABLET;ORAL 213674-001 Aug 4, 2020 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Astellas XTANDI enzalutamide TABLET;ORAL 213674-002 Aug 4, 2020 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,709,517

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 541571   Start Trial
Australia 2006248109   Start Trial
Australia 2007245022   Start Trial
Brazil PI0610359   Start Trial
Brazil PI0709682   Start Trial
Canada 2608436   Start Trial
Canada 2648139   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.